of September 30, 2018 and December 31, 2017, Asterias did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii)
of SEC Regulation S-K.
and Qualitative Disclosures about Market Risk
Currency Exchange Risk
is not presently exposed in a significant degree to foreign exchange currency risks because Asterias is not otherwise conducting
international business at this time, and Asterias does not engage in foreign currency hedging activities. If Asterias engages
in international transactions, Asterias will need to translate foreign currencies into U.S. dollars for reporting purposes, and
currency fluctuations could have a greater impact on Asterias’ financial results.
places some of its cash in U.S. banks and invest most of Asterias’ cash in money market funds. Deposits with banks may temporarily
exceed the amount of insurance provided on such deposits. Asterias will monitor the cash balances in the accounts and adjust the
cash balances as appropriate, but if the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured
portion of the deposit could be lost, in whole or in part, if the bank were to fail. Asterias’ investments in money market
funds are not insured or guaranteed by the United States government or any of its agencies.
invests most of its cash in money market funds. The primary objective of Asterias’ investments will be to preserve principal
and liquidity while earning a return on Asterias’ invested capital, without incurring significant risks. Asterias’
future investment income is not guaranteed and may fall short of expectations due to changes in prevailing interest rates, or
Asterias may suffer losses in principal if the net asset value of a money market fund falls below $1 per share.
of February 1, 2019, Asterias held 2,621,811 BioTime Common Shares at fair value. Asterias’ marketable equity securities’
values are subject to changes in the stock price of BioTime. BioTime Common Shares trade on the NYSE American under the ticker
“BTX”. As of February 1, 2019 the 52-week high/low stock price per share range for BioTime shares were $2.89